Funding for this research was provided by:
National Human Genome Research Institute (1R01HG009671)
Received: 25 February 2020
Accepted: 6 April 2020
First Online: 15 May 2020
Ethics approval and consent to participate
: This project is approved by the Geisinger Institutional Review Board (IRB# 2018–0419). A 2.3.in the MyCode® Community Health Initiative biobank at Geisinger. Parents of prospective participants will receive a letter describing the study, elements of informed consent, and an opportunity to opt out of additional study contact. Two weeks later, research staff will call those who have not opted out of study contact and offer an in-person visit to discuss the study. Parents of pediatric participants in this study will provide written informed consent and pediatric participants age 7–17 years will provide written assent prior to participation.
: Not Applicable.
: JMS, JKW, SJ, AKR, MSW, FDD, JH, YH, HLK, MNM, JM, SMO, JP, ACS, and AHB declare that they have no competing interests. Dr. Angela R. Bradbury (ARB) has received honoraria from AstraZeneca and Merck.